<DOC>
	<DOCNO>NCT00416273</DOCNO>
	<brief_summary>The purpose study determination event-free survival without Bortezomib consolidation therapy day first chemotherapeutic , myeloma-specific therapy measure , occurrence progression/recurrence occurrence death .</brief_summary>
	<brief_title>A Study Bortezomib Consolidation Therapy Patients With Multiple Myeloma</brief_title>
	<detailed_description>This two-arm ( group ) , open-label ( people know identity intervention ) , prospective ( study patient identify follow forward time outcome study ) randomize ( study medication assign chance ) , multi-center study . Approximately 385 patient enrol study . Patients randomly assign treatment observation group ratio 1:1 . The study duration screen study end 27 week . Then patient observe last included patient complete 30 month post observational phase . The patient treatment arm receive 4 cycle therapy . Each cycle last 35 day . Safety evaluation include assessment adverse event , vital sign , physical examination , electrocardiogram , clinical laboratory test .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Patients multiple myeloma prior therapy consist remission induction therapy high dose chemotherapy follow stem cell transplantation Women must postmenopausal use safe contraception method Creatinin clearance high 30 ml/min whole blood count within acceptable range No asecretory multiple myeloma History allergic reaction bortezomib mannitol Expected life expectancy le 3 month No malignant disease beside basalioma either exist history No history severe cardiopulmonary disease Seizures</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Bortezomib</keyword>
	<keyword>PS341</keyword>
	<keyword>Proteasome inhibitor</keyword>
	<keyword>Consolidation therapy</keyword>
</DOC>